Navigation Links ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals' CEO

NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- On August 7, J. J. Finkelstein, Chief Executive Officer of RegeneRx Biopharmaceuticals (Amex: RGN) updated the investment community in an all-new interview with Topics covered in the interview include RegeneRx Biopharmaceuticals' clinical trials, market potential, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window.

About RegeneRx Biopharmaceuticals:

RegeneRx, headquartered in Bethesda, Maryland, is a publicly-traded biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. The Company is currently sponsoring five clinical trials for dermal wound healing, ophthalmic wound healing, and cardiovascular protection and regeneration after heart attack.

RegeneRx utilizes an outsourcing business model in order to effectively control costs while focusing on clinical development of its drug candidates. This model is used for research and development, manufacturing, drug formulation and clinical trials, as well as for other functions critical to its mission and enhances RegeneRx's ability to allocate resources rapidly to different projects without having to invest in infrastructure.

For more information about this Company, please visit

About is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. ( The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns, a financial social network for investors, and Financial Filings Corp. (, a provider of media and compliance solutions to publicly traded companies. In addition to, WallStreet Direct, Inc. owns and operates WallStRadio (, a business and finance podcast Web site. Financial Filings Corp. has received two hundred eighty dollars from RegeneRx Biopharmaceuticals, Inc. as reimbursement for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit




SOURCE Financial Filings Corp.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
4. NCCN Updates Esophageal and Gastric Cancer Guidelines
5. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
6. Tercica to Present at Investment Conferences
7. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
8. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer
11. Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference
Post Your Comments:
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... au traitement photodynamique au Bremachlorin contre le cancer ... approche consistant à combiner l,immunothérapie au traitement photodynamique ... --> Une nouvelle approche consistant ... contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at ... Michigan, have come together on Thanksgiving Day to share the things that they ... on the Serenity Point YouTube channel, patients displayed what they wrote on index ...
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the world-class ... improve system efficiency and reliability. , The new Q-Suite 6 platform is based on ... avoids locking itself into a specific piece of software for many key components of ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of the ... stellar workplace culture with the company’s Cincinnati office being named a finalist among ... was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati Best ...
Breaking Medicine News(10 mins):